BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 35943886)

  • 1. A Retrospective Evaluation of the Diagnostic Performance of an Interdependent Pairwise MicroRNA Expression Analysis with a Mutation Panel in Indeterminate Thyroid Nodules.
    Finkelstein SD; Sistrunk JW; Malchoff C; Thompson DV; Kumar G; Timmaraju VA; Repko B; Mireskandari A; Evoy-Goodman LA; Massoll NA; Lupo MA
    Thyroid; 2022 Nov; 32(11):1362-1371. PubMed ID: 35943886
    [No Abstract]   [Full Text] [Related]  

  • 2. The role of the ThyGeNEXT oncogene panel used in combination with the expanded miRNA panel ThyraMIRv2 in Indeterminate thyroid nodules: A large, blinded, real-world, observational study.
    Verma T; Marshall C; Dantey KE; Thompson DV; Banizs A; Finkelstein SD; DelTondo J
    Cancer Cytopathol; 2024 May; ():. PubMed ID: 38814813
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiplatform molecular test performance in indeterminate thyroid nodules.
    Lupo MA; Walts AE; Sistrunk JW; Giordano TJ; Sadow PM; Massoll N; Campbell R; Jackson SA; Toney N; Narick CM; Kumar G; Mireskandari A; Finkelstein SD; Bose S
    Diagn Cytopathol; 2020 Dec; 48(12):1254-1264. PubMed ID: 32767735
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analytical and clinical validation of pairwise microRNA expression analysis to identify medullary thyroid cancer in thyroid fine-needle aspiration samples.
    Ciarletto AM; Narick C; Malchoff CD; Massoll NA; Labourier E; Haugh K; Mireskandari A; Finkelstein SD; Kumar G
    Cancer Cytopathol; 2021 Mar; 129(3):239-249. PubMed ID: 33017868
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical performance of multiplatform mutation panel and microRNA risk classifier in indeterminate thyroid nodules.
    Sistrunk JW; Shifrin A; Frager M; Bardales RH; Thomas J; Fishman N; Goldberg P; Guttler R; Grant E
    J Am Soc Cytopathol; 2020; 9(4):232-241. PubMed ID: 32247769
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Performance of a Multigene Genomic Classifier in Thyroid Nodules With Indeterminate Cytology: A Prospective Blinded Multicenter Study.
    Steward DL; Carty SE; Sippel RS; Yang SP; Sosa JA; Sipos JA; Figge JJ; Mandel S; Haugen BR; Burman KD; Baloch ZW; Lloyd RV; Seethala RR; Gooding WE; Chiosea SI; Gomes-Lima C; Ferris RL; Folek JM; Khawaja RA; Kundra P; Loh KS; Marshall CB; Mayson S; McCoy KL; Nga ME; Ngiam KY; Nikiforova MN; Poehls JL; Ringel MD; Yang H; Yip L; Nikiforov YE
    JAMA Oncol; 2019 Feb; 5(2):204-212. PubMed ID: 30419129
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical utility of a microRNA classifier in cytologically indeterminate thyroid nodules with RAS mutations: A multi-institutional study.
    Tumati A; Egan CE; Lee-Saxton YJ; Marshall TE; Lee J; Jain K; Heymann JJ; Gokozan H; Azar SA; Schwarz J; Keutgen XM; Laird AM; Beninato T; Zarnegar R; Fahey TJ; Finnerty BM
    Surgery; 2024 Jan; 175(1):234-240. PubMed ID: 37907382
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular Testing for miRNA, mRNA, and DNA on Fine-Needle Aspiration Improves the Preoperative Diagnosis of Thyroid Nodules With Indeterminate Cytology.
    Labourier E; Shifrin A; Busseniers AE; Lupo MA; Manganelli ML; Andruss B; Wylie D; Beaudenon-Huibregtse S
    J Clin Endocrinol Metab; 2015 Jul; 100(7):2743-50. PubMed ID: 25965083
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preoperative detection of malignancy in fine-needle aspiration cytology (FNAC) smears with indeterminate cytology (Bethesda III, IV) by a combined molecular classifier.
    Titov S; Demenkov PS; Lukyanov SA; Sergiyko SV; Katanyan GA; Veryaskina YA; Ivanov MK
    J Clin Pathol; 2020 Nov; 73(11):722-727. PubMed ID: 32213552
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Performance of a Genomic Sequencing Classifier for the Preoperative Diagnosis of Cytologically Indeterminate Thyroid Nodules.
    Patel KN; Angell TE; Babiarz J; Barth NM; Blevins T; Duh QY; Ghossein RA; Harrell RM; Huang J; Kennedy GC; Kim SY; Kloos RT; LiVolsi VA; Randolph GW; Sadow PM; Shanik MH; Sosa JA; Traweek ST; Walsh PS; Whitney D; Yeh MW; Ladenson PW
    JAMA Surg; 2018 Sep; 153(9):817-824. PubMed ID: 29799911
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted Next Generation Sequencing with ThyroSeq v2.1 for Indeterminate Thyroid Nodules in Clinical Practice.
    Witt RL
    Del Med J; 2016 Dec; 88(12):366-372. PubMed ID: 29461717
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of Molecular Testing Techniques for Diagnosis of Indeterminate Thyroid Nodules: A Randomized Clinical Trial.
    Livhits MJ; Zhu CY; Kuo EJ; Nguyen DT; Kim J; Tseng CH; Leung AM; Rao J; Levin M; Douek ML; Beckett KR; Cheung DS; Gofnung YA; Smooke-Praw S; Yeh MW
    JAMA Oncol; 2021 Jan; 7(1):70-77. PubMed ID: 33300952
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thyroseq v3, Afirma GSC, and microRNA Panels Versus Previous Molecular Tests in the Preoperative Diagnosis of Indeterminate Thyroid Nodules: A Systematic Review and Meta-Analysis.
    Silaghi CA; Lozovanu V; Georgescu CE; Georgescu RD; Susman S; Năsui BA; Dobrean A; Silaghi H
    Front Endocrinol (Lausanne); 2021; 12():649522. PubMed ID: 34054725
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The first Canadian experience with the Afirma® gene expression classifier test.
    Kay-Rivest E; Tibbo J; Bouhabel S; Tamilia M; Leboeuf R; Forest VI; Hier MP; Savoury L; Payne RJ
    J Otolaryngol Head Neck Surg; 2017 Apr; 46(1):25. PubMed ID: 28372589
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The utility of ThyroSeq
    Li W; Justice-Clark T; Cohen MB
    Cytopathology; 2021 Jul; 32(4):505-512. PubMed ID: 33914382
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Afirma Gene Sequencing Classifier Compared with Gene Expression Classifier in Indeterminate Thyroid Nodules.
    Endo M; Nabhan F; Porter K; Roll K; Shirley LA; Azaryan I; Tonkovich D; Perlick J; Ryan LE; Khawaja R; Meng S; Phay JE; Ringel MD; Sipos JA
    Thyroid; 2019 Aug; 29(8):1115-1124. PubMed ID: 31154940
    [No Abstract]   [Full Text] [Related]  

  • 17. A Novel Risk Stratification System for Thyroid Nodules With Indeterminate Cytology-A Pilot Cohort Study.
    Gomes-Lima CJ; Auh S; Thakur S; Zemskova M; Cochran C; Merkel R; Filie AC; Raffeld M; Patel SB; Xi L; Wartofsky L; Burman KD; Klubo-Gwiezdzinska J
    Front Endocrinol (Lausanne); 2020; 11():53. PubMed ID: 32132976
    [No Abstract]   [Full Text] [Related]  

  • 18. Next-Generation Sequencing Identifies a Highly Accurate miRNA Panel That Distinguishes Well-Differentiated Thyroid Cancer from Benign Thyroid Nodules.
    Mazeh H; Deutch T; Karas A; Bogardus KA; Mizrahi I; Gur-Wahnon D; Ben-Dov IZ
    Cancer Epidemiol Biomarkers Prev; 2018 Aug; 27(8):858-863. PubMed ID: 30049841
    [No Abstract]   [Full Text] [Related]  

  • 19. Utility of a multigene testing for preoperative evaluation of indeterminate thyroid nodules: A prospective blinded single center study in China.
    Song Y; Xu G; Ma T; Zhu Y; Yu H; Yu W; Wei W; Wang T; Zhang B
    Cancer Med; 2020 Nov; 9(22):8397-8405. PubMed ID: 32976686
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A panel of four miRNAs accurately differentiates malignant from benign indeterminate thyroid lesions on fine needle aspiration.
    Keutgen XM; Filicori F; Crowley MJ; Wang Y; Scognamiglio T; Hoda R; Buitrago D; Cooper D; Zeiger MA; Zarnegar R; Elemento O; Fahey TJ
    Clin Cancer Res; 2012 Apr; 18(7):2032-8. PubMed ID: 22351693
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.